Why ArQule’s Early-Stage Hematology Study Could Be Transformational
ArQule shares jumped early on Friday after the firm announced preliminary results from an early-stage study in patients with relapsed or refractory hematologic malignancies at the 2019 European........»»
AIM ImmunoTech"s Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
read more.....»»
Karyopharm Stock Is Trading Higher After China"s NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
read more.....»»
Pfizer starts early-stage study of oral COVID-19 treatment
Shares of Pfizer Inc. were down 1.1% in trading on Tuesday after the drug maker said it initiated a Phase 1 cl.....»»
Inhibrx"s INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a pre.....»»
Longeveron"s Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart Defect
read more.....»»
AstraZeneca/Merck"s PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis
read more.....»»
J&J"s COVID-19 vaccine candidate shows it generates antibodies in early-stage trial
Shares of Johnson & Johnson gained 1.7% in premarket trading on Thursday, the day after a study published in the New England Journal of Medicine showed that its COVID-19 vaccine candidate generated neutral.....»»
Why This Late-Stage Kidney Cancer Study Could Be Huge
Exelixis stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb, announced positive late-stage results from its kidney cancer study......»»
Why Immunomedics Stock More Than Doubled
Immunomedics shares soared on Monday after the announcements that a late-stage breast cancer study was halted early and a new chief executive officer was named......»»
Fate Therapeutics" stock rises on early-stage cancer drug data
Shares of Fate Therapeutics gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in.....»»
Crispr"s Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study
Crispr Therapeutics AG (NASDAQ: CRSP) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's 0.....»»
Why Investors Are Pumping the Brakes on NextCure’s Cancer Treatment
NextCure updated clinical results from its early stage cancer study at the Society for Immunotherapy of Cancer annual meeting. As a result, NextCure shares were crushed on Monday......»»
Seattle Genetics Impresses At ESMO With Early Stage Study For Bladder Cancer Patients
Seattle Genetics Impresses At ESMO With Early Stage Study For Bladder Cancer Patients.....»»
Major Duchenne Muscular Dystrophy Trial Is Ready to Launch
Catabasis Pharma shares jumped early on Tuesday after the firm announced that it had completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment........»»
Amgen’s Lung Cancer Study Needs to Take a Breather
Amgen shares dropped on Monday after the firm released additional data from its early-stage lung cancer study. Specifically this data is coming from the ongoing Phase 1 study evaluating AMG 510 in........»»
Why This New Dementia Study Is a Huge Hit
Acadia Pharmaceuticals shares rose sharply early Monday after the firm announced that its late-stage dementia study met its primary endpoint......»»